WallStreetZenWallStreetZen

NASDAQ: RLAY
Relay Therapeutics Inc Stock

$8.16+0.59 (+7.79%)
Updated Mar 27, 2024
RLAY Price
$8.16
Fair Value Price
-$0.00
Market Cap
$1.07B
52 Week Low
$5.95
52 Week High
$19.23
P/E
-2.92x
P/B
1.42x
P/S
52.83x
PEG
N/A
Dividend Yield
N/A
Revenue
$25.55M
Earnings
-$341.97M
Gross Margin
100%
Operating Margin
-1,338.66%
Profit Margin
-1,338.7%
Debt to Equity
0.12
Operating Cash Flow
-$300M
Beta
1.59
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A

RLAY Overview

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RLAY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RLAY ($8.16) is overvalued by 1,871,718.6% relative to our estimate of its Fair Value price of -$0.00 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RLAY ($8.16) is not significantly undervalued (1,871,718.6%) relative to our estimate of its Fair Value price of -$0.00 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RLAY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RLAY due diligence checks available for Premium users.

Be the first to know about important RLAY news, forecast changes, insider trades & much more!

RLAY News

Valuation

RLAY fair value

Fair Value of RLAY stock based on Discounted Cash Flow (DCF)
Price
$8.16
Fair Value
-$0.00
Undervalued by
1,871,718.60%
RLAY ($8.16) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RLAY ($8.16) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RLAY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RLAY price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.92x
Industry
14.3x
Market
44.45x

RLAY price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.42x
Industry
6.2x
RLAY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RLAY's financial health

Profit margin

Revenue
-$1.0k
Net Income
-$83.5M
Profit Margin
8,349,500%
RLAY's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
RLAY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$844.0M
Liabilities
$92.0M
Debt to equity
0.12
RLAY's short-term assets ($770.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RLAY's short-term assets ($770.10M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RLAY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RLAY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$89.2M
Investing
$59.7M
Financing
$21.9M
RLAY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RLAY vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
RLAY$1.07B+7.79%-2.92x1.42x
ZNTL$1.08B+7.81%-3.40x2.46x
BCRX$1.06B+2.79%-4.36x-2.33x
ETNB$1.06B+0.98%-5.66x1.97x
CNTA$1.08B+3.16%-6.77x4.18x

Relay Therapeutics Stock FAQ

What is Relay Therapeutics's quote symbol?

(NASDAQ: RLAY) Relay Therapeutics trades on the NASDAQ under the ticker symbol RLAY. Relay Therapeutics stock quotes can also be displayed as NASDAQ: RLAY.

If you're new to stock investing, here's how to buy Relay Therapeutics stock.

What is the 52 week high and low for Relay Therapeutics (NASDAQ: RLAY)?

(NASDAQ: RLAY) Relay Therapeutics's 52-week high was $19.23, and its 52-week low was $5.95. It is currently -57.57% from its 52-week high and 37.14% from its 52-week low.

How much is Relay Therapeutics stock worth today?

(NASDAQ: RLAY) Relay Therapeutics currently has 131,179,034 outstanding shares. With Relay Therapeutics stock trading at $8.16 per share, the total value of Relay Therapeutics stock (market capitalization) is $1.07B.

Relay Therapeutics stock was originally listed at a price of $35.05 in Jul 16, 2020. If you had invested in Relay Therapeutics stock at $35.05, your return over the last 3 years would have been -76.72%, for an annualized return of -38.48% (not including any dividends or dividend reinvestments).

How much is Relay Therapeutics's stock price per share?

(NASDAQ: RLAY) Relay Therapeutics stock price per share is $8.16 today (as of Mar 27, 2024).

What is Relay Therapeutics's Market Cap?

(NASDAQ: RLAY) Relay Therapeutics's market cap is $1.07B, as of Mar 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Relay Therapeutics's market cap is calculated by multiplying RLAY's current stock price of $8.16 by RLAY's total outstanding shares of 131,179,034.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.